Results 11 to 20 of about 67,898 (115)

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

Journal of Clinical Oncology, 2021
PURPOSE Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System.
M. Irwin, A. Naranjo, Fan F. Zhang, S. Cohn, W. London, J. Gastier-Foster, N. Ramirez, R. Pfau, S. Reshmi, Elizabeth Wagner, J. Nuchtern, S. Asgharzadeh, H. Shimada, J. Maris, R. Bagatell, Julie R. Park, M. Hogarty   +16 more
semanticscholar   +1 more source

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis

Nature Cancer, 2022
Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces
H. Alborzinia, Andrés F. Flórez, Sina Kreth, L. Brückner, Umut Yildiz, Moritz Gartlgruber, Dorett I Odoni, Gernot Poschet, K. Garbowicz, Chunxuan Shao, C. Klein, Jasmin Meier, Petra Zeisberger, Michal Nadler-Holly, M. Ziehm, F. Paul, J. Burhenne, E. Bell, Marjan Shaikhkarami, Roberto Würth, S. Stainczyk, Elisa M Wecht, Jochen Kreth, M. Büttner, Naveed Ishaque, M. Schlesner, B. Nicke, Carlo Stresemann, Maria Llamazares-Prada, J. Reiling, M. Fischer, I. Amit, M. Selbach, C. Herrmann, S. Wölfl, K. Henrich, T. Höfer, A. Trumpp, F. Westermann   +38 more
semanticscholar   +1 more source

Neuroblastoma: When differentiation goes awry

Neuron, 2022
Neuroblastoma is a leading cause of cancer-related death in children. Accumulated data suggest that differentiation arrest of the neural-crest-derived sympathoadrenal lineage contributes to neuroblastoma formation.
Maged Zeineldin, Anand G. Patel, M. Dyer
semanticscholar   +1 more source

Immunotherapy of Neuroblastoma: Facts and Hopes

Clinical Cancer Research, 2022
While the adoption of multimodal therapy including surgery, radiation, and aggressive combination chemotherapy has improved outcomes for many children with high-risk neuroblastoma, we appear to have reached a plateau in what can be achieved with ...
John Anderson, R. Majzner, P. Sondel
semanticscholar   +1 more source

Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia [PDF]

, 2017
La hiponatremia se define como una concentración sérica de sodio
Allolio, Bruno, Annane, Djillali, Ball, Steve, Bichet, Daniel, Biesen, Wim van, Decaux, Guy, Fenske, Wiebke, González-Espinoza, Liliana, Haller, Maria, Hoorn, Ewout J., Hyponatraemia Guideline Development Group, Ichai, Carole, Joannidis, Miachael, Nagler, Evi, Ortiz, Alberto, Soupart, Alain, Spasovski, Goce, Vanholder, Raymond, Veer, Sabine van der, Zietse, Robert   +19 more
core   +7 more sources

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies

Current Oncology Reports, 2022
The evolving information of the initiation, tumor cell heterogeneity, and plasticity of childhood neuroblastoma has opened up new perspectives for developing therapies based on detailed knowledge of the disease.
K. Lundberg, D. Treis, J. Johnsen
semanticscholar   +1 more source

MYCN Function in Neuroblastoma Development

Frontiers in Oncology, 2021
Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest ...
Jörg Otte, Cecilia Dyberg, Adena Pepich, J. Johnsen   +3 more
semanticscholar   +1 more source

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Nature Communications, 2021
The ability to utilize preclinical models to predict the clinical toxicity of chimeric antigen receptor (CAR) T cells in solid tumors is tenuous, thereby necessitating the development and evaluation of gated systems.
B. Moghimi, Sakunthala Muthugounder, S. Jambon, Rachelle Tibbetts, Long T. Hung, H. Bassiri, M. Hogarty, D. Barrett, H. Shimada, S. Asgharzadeh   +9 more
semanticscholar   +1 more source

MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

Cancer Research, 2021
The study shows how MYCN increases intracellular iron levels and subsequent GSH pathway activity and demonstrates the antitumor activity of FDA-approved SAS and auranofin in patient-derived xenograft models of MYCN-amplified neuroblastoma.
K. Floros, Jinyang Cai, Sheeba Jacob, Richard I. J. Kurupi, Carter K. Fairchild, Mayuri Shende, Colin M. Coon, Krista M. Powell, B. Belvin, Bin Hu, Madhavi Puchalapalli, S. Ramamoorthy, K. Swift, J. Lewis, M. Dozmorov, J. Glod, Jennifer E. Koblinski, S. Boikos, A. Faber   +18 more
semanticscholar   +1 more source

Estesioneuroblastoma: um tumor heteróclito da oncologia clínica / Esthesioneuroblastoma: A Heteroclite Tumor of Clinical Oncology

ID on line REVISTA DE PSICOLOGIA, 2019
O estesioneuroblastoma é um tumor raro originário no epitélio olfativo sem um tratamento estabelecido. A combinação de ressecção craniofacial (RCF) e radioterapia (RT) parece associar-se aos melhores resultados.
Maria Clara Rodrigues Lima Medeiros, Caio Andrade Nascimento, Laysa Andrade Almeida Moraes, Igor Marcelo Castro e Silva   +3 more
semanticscholar   +1 more source